6-Isopropyl-6-nor-lysergic acid diethylamide

6-Isopropyl-6-nor-lysergic acid diethylamide

Systematic (IUPAC) name
(8β)-N,N-Diethyl-6-isopropyl-9,10-didehydroergoline-8-carboxamide
Clinical data
Legal status	Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.
Routes of administration	Oral
(verify)

IP-LAD, known also as 6-isopropyl-6-nor-lysergic acid diethylamide, is an analogue of LAD developed by the team of David E. Nicols. In studies on mice, it was found to be approximately 40% the potency of LAD, compared to the 60% increase in potency seen with ETH-LAD and roughly equivalent potency in AL-LAD and PRO-LAD.